Overview

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Status:
Completed
Trial end date:
2020-07-06
Target enrollment:
Participant gender:
Summary
Primary Objective: To assess the efficacy of MEDI4736 monotherapy in terms of ORR
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Collaborator:
PRA Health Sciences
Treatments:
Antibodies, Monoclonal
Durvalumab